VDAC was demonstrated to be able to dictate cell death and survival, that is, a decrease in VDAC reduces cell viability
A 2025 analysis found that GLP-1 agonists given for diabetes were associated with a reduced risk of substance use among hundreds of thousands of United States Veterans and a 2024 examination of over 500k patients 4 Qeadan, F., McCunn, A., & Tingey, B
Key Benefits Backed by Human Trials Boosts Satiety by Up to 65% Users in clinical studies of Metabolaid and CQR-300 reported significantly reduced hunger, particularly before and between meals
Parental vaccine safety concerns in 2009
Although these trials primarily enrolled individuals with relatively low DKD risk and were not designed to evaluate kidney outcomes specifically, exploratory analyses consistently indicated slower kidney disease progression across diverse eGFR and albuminuria levels [39-44]